Eric Dube
Principal executive officer pay for Eric Dube, by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
Travere Therapeutics, Inc. (TVTX) FY2020–FY2025
Lagged peersTSR -27% vs peer group -1% over FY2020–FY2025
Paid for declineCAP $10,291,743→$24,497,149 while $100 invested went $191.94→$140.19 (FY2020–FY2025)
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2020 | $5.4M | $10.3M |
| FY2021 | $5.7M | $6.6M |
| FY2022 | $5.8M | $687,242 |
| FY2023 | $7.6M | $885,487 |
| FY2024 | $5.2M | $10.9M |
| FY2025 | $8.5M | $24.5M |
The company's "$100 invested" index ran $191.94 at FY2020 → $140.19 by FY2025 — an annualized return of -6.1%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: -6.1%/yr at TVTX ( FY2020–FY2025). See the CEO track-record ranking for context.